CONCORD, Mass.–(BUSINESS WIRE)–ClearB Therapeutics, Inc., a company developing CLB-3000, a therapeutic vaccine designed to drive functional cure of hepatitis B, announced today that two abstracts were accepted for poster presentation at the European Association for the Study of the Liver (EASL) International Liver Congress (ILC) 2023, taking place in Vienna, Austria June 21 – 24, 2023.

“Chronic Hepatitis B (CHB) infection remains a substantial global health care problem in need of effective antiviral and immunomodulatory therapies likely in combination. We believe that re-education of patients’ immune systems with ClearB’s therapeutic vaccine could become an important component of such treatment regimens.”

Tweet this

“As we continue to progress our therapeutic vaccine candidate, CLB-3000, toward first in human trials, we are excited to share our preclinical data with the Hepatitis B community” said Chris Stevens, MD, CMO for the company. “Chronic Hepatitis B (CHB) infection remains a substantial global health care problem in need of effective antiviral and immunomodulatory therapies likely in combination. We believe that re-education of patients’ immune systems with ClearB’s therapeutic vaccine could become an important component of such treatment regimens.”

Abstract Number: 2515 / SAT-197
Abstract Title: Therapeutic vaccine candidate CLB-3000 (CLB-405 and CLB-505 adjuvanted with Alhydrogel): a Good Laboratory Practice (GLP)-compliant 15-week intramuscular toxicity study in rabbits with a 4-week recovery
Date: Saturday, June 24, 2023
Time: 9:00 AM GMT+1
Presenter Name: Dr. Aileen Rubio, ClearB Therapeutics

Abstract Number: 2543 / SAT-191
Abstract Title: A monoclonal antibody 4G2 exhibits anti-viral activity in persistent HBV infection mouse models
Date: Saturday, June 24, 2023
Time: 9:00 AM GMT+1
Presenter Name: Dr. Aditi Deshpande, ClearB Therapeutics

For more information regarding EASL 2023 please visit
EASL Congress 2023 – The International Liver Congress

About ClearB Therapeutics
ClearB Therapeutics was co-founded in 2017 by Morningside Ventures in collaboration with Professor Stephen Locarnini and the Victoria Infectious Diseases Reference Laboratory in Melbourne, Australia. ClearB is working to develop therapeutic vaccines designed to drive functional cure of hepatitis B. The work is grounded in proprietary insights derived from studying rare-event infection resolution in patients who suffer from chronic hepatitis B. For more information, please visit https://clearbtherapeutics.com/.